Fig. 5
From: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Inhibition of miR-21 and WIP1 kills HER2+ breast cancer cells harboring 17q23 amplicon. a–c HER18 (a), BT-474 (b) or MDA-MB-453 (c) cells were incubated with or without the WIP1 inhibitor GSK2830371 at the indicated concentrations for 72 h. The cell viability was then measured and these results are presented as % vehicle ± SD. Protein levels are shown at the bottom of each panel by immunoblotting. d, e HER18 (d) or BT-474 (e) cells with or without Dox-induced miR-21 knockdown were incubated indicated concentrations of GSK2830371 for 72 h. The cell viability was then measured and these results are presented as % vehicle ± SD (left panels). The cell lysates were subjected to Western blot analyses with the indicated antibodies (middle panels). Knockdown efficiency of miR-21 was measured by luciferase reporter assay (right panels). *p < 0.05; **p < 0.01; unpaired 2-tailed t-test was used (d, e). Data are presented as mean ± SD and are representative of 3 independent experiments
